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Abstract
Background: Arthritis gloves are regularly provided as part of the management of people with rheumatoid arthritis
(RA) and undifferentiated (early) inflammatory arthritis (IA). Usually made of nylon and elastane (i.e. Lycra®), these
arthritis gloves apply pressure with the aims of relieving hand pain, stiffness and improving hand function.
However, a systematic review identified little evidence supporting their use. We therefore designed a trial to
compare the effectiveness of the commonest type of arthritis glove provided in the United Kingdom (Isotoner
gloves) (intervention) with placebo (control) gloves (i.e. larger arthritis gloves providing similar warmth to the
intervention gloves but minimal pressure only) in people with these conditions.
Methods: Participants aged 18 years and over with RA or IA and persistent hand pain will be recruited from National
Health Service Trusts in the United Kingdom. Following consent, participants will complete a questionnaire booklet, then
be randomly allocated to receive intervention or placebo arthritis gloves. Within three weeks, they will be fitted with the
allocated gloves by clinical specialist rheumatology occupational therapists. Twelve weeks (i.e. the primary endpoint) after
completing the baseline questionnaire, participants will complete a second questionnaire, including the same measures
plus additional questions to explore adherence, benefits and problems with glove-wear. A sub-sample of participants
from each group will be interviewed at the end of their participation to explore their views of the gloves received. The
clinical effectiveness and cost-effectiveness of the intervention, compared to placebo gloves, will be evaluated over
12 weeks. The primary outcome measure is hand pain during activity. Qualitative interviews will be thematically analysed.
Discussion: This study will evaluate the commonest type of arthritis glove (Isotoner) provided in the NHS (i.e. the
intervention) compared to a placebo glove. The results will help occupational therapists, occupational therapy services
and people with arthritis make informed choices as to the value of arthritis gloves. If effective, arthritis gloves should
become more widely available in the NHS to help people with RA and IA manage hand symptoms and improve
performance of daily activities, work and leisure. If not, services can determine whether to cease supplying these to
reduce service costs.
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Background
Rheumatoid arthritis (RA) is a chronic inflammatory con-
dition causing joint pain, swelling (synovitis), stiffness and
muscle loss around affected joints [1]. It affects 1% of the
population, and twice as many women as men. Peak onset
is in the 40-60 age group, it is incurable and causes signifi-
cant disability if untreated [2, 3]. RA is managed with
disease modifying anti-rheumatic drugs (DMARDs), re-
habilitation and self-management education. People with
persistent synovitis, where other pathologies are ruled out
(i.e. undifferentiated inflammatory arthritis (IA), who do
not yet meet the criteria for RA [4]), also require specialist
care and DMARDs, and are thus treated as if they have
RA [1]. Most people with IA and RA have symptoms in
both hands, resulting in problems with everyday activities,
work and leisure. Many experience frustration and distress
because of hand pain, stiffness and disability. A third are
work disabled within 5 years [1].
Arthritis gloves are commonly provided by Rheumatology
occupational therapists to people with IA or RA. These
are worn for pain relief during the day or night and to im-
prove hand function during the day. We surveyed
Rheumatology occupational therapists,identifying that
most provide arthritis gloves [5]. Provision varies consid-
erably between occupational therapists but averages a
third of the patients they see. The most common make of
glove provided is the mid-finger Isotoner glove (i.e. finger
tips exposed to aid hand function) and the next common-
est are Jobskin and Norco oedema gloves [5, 6]. Provision
of gloves appears to have risen following a randomised
controlled trial (RCT) demonstrating an alternative treat-
ment (resting splints) was ineffective in early RA [7].
(Glove photographs are in Additional file 1: study
information).
Arthritis gloves are usually made of nylon and elastane
(i.e. Lycra®). They are thought to impact on hand symp-
toms through providing compression (pressure) and/or
warmth. Some models apply both and others warmth
only. Isotoner gloves, containing 20% elastane, exert the
highest pressure of those makes available, at 23-32 mmHg
[8]. Other makes exert less as these contain less elastane
(e.g. the Jobskin classic oedema gloves exert 15-25 mm
Hg and contain 11% elastane [9]). When properly fitted
(to be a “snug fit”), the gloves apply controlled pressure to
the hand [10]. The pressure is thought to: (a) remove
extracellular fluid, thus reducing pain, stiffness and im-
proving finger motion; and (b) increase blood flow and
consequently warmth, reducing pain [10, 11]. The glove
material also provides warmth, contributing to pain relief.
Makes of arthritis gloves, which specifically apply pressure,
are termed compression or oedema gloves. It is unclear
what a therapeutic level of pressure is, as this has not been
identified through physiological studies. However, based on
pressure information from manufacturers, therapists
consider this is between 15-32 mmHg. We also
hypothesize that arthritis gloves provide tactile feedback to
the glove wearer reminding them to take more care of their
hand joints. Potentially, all models of glove (however much
pressure and/or warmth they apply) may be acting through
this mechanism. This effect was hypothesized in a pilot
clinical effectiveness and efficacy trial of thumb splints
[12].
Despite their widespread use, evidence for the effect-
iveness of arthritis gloves is inconclusive. In a recent
systematic review, we identified only four trials evaluat-
ing arthritis gloves. Trials were small and results incon-
clusive [13]. We therefore developed this randomized
controlled trial to evaluate the effectiveness and cost-
effectiveness of the most commonly used arthritis glove
(i.e. Isotoner) in people with RA or IA.
Feasibility study
We conducted a feasibility study among patients with IA
or RA (n = 39) in 10 Occupational Therapy departments in
Northwest England evaluating mid-finger Isotoner gloves
(as these are the commonest type provided and apply the
highest pressure). During this study we standardised
arthritis glove eligibility criteria, glove treatment protocols
(including the arthritis glove patient information sheet)
with participating therapists (North-West College of
Occupational Therapy Specialist Section in Rheumatology:
NWCOTSS-R arthritis glove protocol [14]. The results of
the study are reported elsewhere [15].
Objectives
The primary objective is to assess whether there is a clin-
ically important difference in self-reported dominant hand
pain during daytime activity between participants with RA
or IA receiving intervention gloves (Isotoner gloves) in
addition to usual care compared to participants receiving
placebo gloves (Jobskin classic oedema gloves fitted at
least one size too big to ensure similar warmth is provided
but minimal pressure only is applied), plus usual care.
The secondary objectives are to:
i. assess the effectiveness of intervention gloves,
relative to placebo gloves on self-reported:
non-dominant hand pain during activity; dominant
and non-dominant nocturnal hand pain; hand pain
during the day at rest; hand stiffness; hand joint
swelling; and hand function.
ii. evaluate the cost-effectiveness of arthritis gloves
compared with placebo gloves, taking into account
the cost of the gloves and other healthcare resources
used by participants.
iii. explore participants’ views of: the effects of arthritis
(intervention) and placebo gloves on hand
symptoms, function, and their daily lives;
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acceptability of glove wear; and how and when they
prefer to use these.
Trial design
The A-GLOVES trial is a pragmatic, patient-blinded,
multi-centre, superiority randomised parallel group trial
of intervention gloves compared to placebo gloves in
people with RA or IA and persistent hand pain affecting
their ability to do daily activities. Analysis will be on an
intention-to-treat basis. Ethical approval for this study
has been obtained from the North of Scotland Local Re-
search Ethics Committee [15-NS-0077]. The study proto-
col was developed using the SPIRIT guidelines [16].
Methods
Study setting
Study participants will be recruited from Rheumatology,
Occupational Therapy and Hand Therapy departments
in 23 hospitals across 17 NHS Trusts in England and
Scotland in the United Kingdom (UK), as arthritis gloves
are most commonly provided by rheumatology occupa-
tional therapists in secondary care.
Eligibility criteria
Inclusion criteria
Patients eligible for the trial must comply with all of the
following at randomization:
1. Aged ≥18 years
2. Diagnosed with RA or IA by a Rheumatology
Consultant
3. Have persistent pain in the proximal interphalangeal
(PIPs) and/or metacarpophalangeal (MCP) joints
causing either
i) difficulty using their hands during the day
(for day wear of gloves) or
ii) disturbed sleep (for night wear of gloves) or
iii) limited ability to use their hands when waking/in
the morning (for night wear of gloves)
4. Willing to wear arthritis gloves and participate in
the trial
5. Able to read and understand English and,
6. Can provide informed consent.
Exclusion criteria
People will be excluded from the study who have:
1. Been diagnosed with other rheumatic conditions,
such as gout, psoriatic arthritis, ankylosing
spondylitis, connective tissue disorders (systemic
lupus, systemic sclerosis), resulting in inflammatory
arthritis in the hand/s
2. Severe Raynaud’s disease or other circulatory
disturbances in the hand
3. Severe neuropathies (nerve damage) in the hand
4. Severe hand deformities
5. Any contraindications to wearing the gloves
(e.g. eczema, infections, broken skin)
6. Previously worn arthritis gloves.
Interventions
Occupational therapist training in glove provision
Interventions will be delivered by 27 National Health
Service (NHS) Rheumatology occupational therapists
(≥Band 6 i.e. clinical specialists). Participating therapists
must attend a one-day clinical trial training programme
delivered by expert Rheumatology occupational thera-
pists and the research team. This will include: trial back-
ground; key study procedures; and practice in providing
the intervention and placebo gloves in a standardised
manner. The A-GLOVES Occupational Therapy Glove
Provision Manual, developed by the research team with
the NW-COTSS-R, will be followed when fitting these
gloves [17].
In addition to the training day, the Trial manager will
conduct site visits to ensure all Principal Investigators, re-
search facilitator/s (i.e. nurses/other staff employed in the
NHS to assist with recruitment into trials) and occupa-
tional therapists involved in the study understand how to
explain the study and arthritis gloves appropriately, to
ensure participants are not unblinded to the intervention.
Glove fitting
The intervention group will receive correctly fitted mid-
finger length Isotoner arthritis gloves. The placebo
group will receive mid-finger length Jobskin classic
oedema gloves fitted at least one size too large, to ensure
they do not apply therapeutic levels of compression.
When fitting gloves, the occupational therapist will
measure participants’ MCP circumference to determine
the glove size required. Therapists will also use their
clinical judgement to determine appropriate fit. Usually,
patients requiring gloves receive these for both hands as
their hand pain and/or swelling is bilateral. However, if
patients have unilateral pain and/or swelling, they are
provided with a glove only for the affected hand.
Additional Interventions
All participants (in both intervention and placebo groups)
will receive a booklet about hand self-management:
“Looking After Your Joints when you have arthritis” [18].
This booklet is widely provided in clinical practice. They
will also receive an information sheet about hand exer-
cises, based on the Strengthening And Stretching For
Rheumatoid Arthritis of the Hand (SARAH) trial hand ex-
ercise programme for RA [19, 20]. During the 12 weeks,
participants will only receive brief training in joint
protection and hand exercises, and this will not use
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cognitive-behavioural approaches. Most departments do
not normally offer behaviourally based joint protection
and/or hand exercise programmes (or where these exist,
such programmes usually have waiting lists), thus partici-
pants are not being disadvantaged.
Modifications
In some instances, a glove may not be fitted if enlarged
PIP joints or finger deformity prevent this. For those
participants with an MCP circumference greater than
23.5 cm (or fingers/hands too large in other respects),
no gloves will be fitted, as an appropriately large size is
not available from manufacturers. If the participant can-
not be fitted with gloves, they still remain in the trial, in
line with “intention-to-treat.”
Adherence
Recommendations for when to wear gloves will be based
on individual needs; most, but not all, patients will be
provided with gloves for both hands. Most people
experience hand pain during the day and are recom-
mended to wear gloves during activity. Those experien-
cing hand pain at night, which interferes with sleep, will
also be recommended to wear gloves at night. Gloves are
not recommended to be worn continually. All participants
will receive written information about glove wear and
care, using the sample information sheet in the A-Gloves
Occupational Therapy Glove Provision Manual [17].
To check for correct glove fit and any problems, occu-
pational therapists will either: within two to four weeks
of glove provision offer a review appointment (in person
or by telephone); or ask the participant to get in contact
if experiencing problems, if this is their normal depart-
mental policy. At the review appointment, participants
will be reminded about their glove wear regimen and the
need to continue to wear the gloves until the 12-week
follow-up questionnaire is completed. At the end of their
trial participation, they will be contacted with further in-
structions about future glove wear.
Adherence to glove wear will be assessed in the 12-week
follow-up questionnaires, by asking participants to de-
scribe their glove wear for right and left hand gloves. This
will include, over the last four weeks, the: average time
worn during the day and/or at night; and the average
number of days per week gloves were worn. The partici-
pant will also be asked to state whether they have obtained
arthritis gloves from elsewhere (if they did so, as it is pos-
sible for patients to purchase gloves in shops and on-line)
and glove wear related to these (if applicable).
Concomitant care
Occupational therapists are asked not to provide resting,
wrist, finger or thumb splints or any other occupational
therapy interventions (apart from joint protection and
hand exercises) to participants whilst they are in the trial
(i.e. during their 12 weeks participation). However, partici-
pants are permitted to attend Physiotherapy for lower limb
interventions if required. Data on participants’ use of con-
comitant care is collected via the 12-week questionnaire.
Outcomes
The primary outcome measure is ‘hand pain during
moderate activity’ which was considered the most im-
portant outcome by glove-users in our feasibility study.
This is measured as hand pain in the dominant hand
during the day, on a typical day, when doing moderate
hand activities, e.g. housework, cooking, Do-It-Yourself,
gardening. In our feasibility study, 2% of participants re-
ceived one glove for their non-dominant hand only. It is
therefore possible that the primary outcome cannot be
collected in a small number of participants in this trial.
Secondary outcome measures are hand pain when
resting and at night; stiffness; self-reported hand condi-
tion; hand function; disability; and resource use and
costs to measure cost-effectiveness of glove provision
(Table 1).
Participant timeline
Participants will complete a baseline questionnaire fol-
lowing consent and prior to the randomisation at week
zero. Within three weeks of randomisation, an occupa-
tional therapy glove fitting appointment will be arranged
to ensure there is sufficient length of time to wear the
gloves prior to the 12-week follow-up. Two to four
weeks after glove fitting (dependent on each depart-
ments’ usual practice), participants will attend an occu-
pational therapy review appointment, either in person or
by telephone, as per departmental policy. Participants
will receive the follow-up questionnaire at 12-week fol-
lowing the date of baseline questionnaire completion.
(See Figs. 1 and 2).
Data collection
The baseline questionnaire includes: demographic
factors i.e. age, gender, living situation, number of
dependents living with them, and employment status;
and condition specific factors, i.e. duration of their
symptoms, time since diagnosis, current medication
regimen and whether they have had a steroid injection/
started on oral steroids within the last six weeks.
Both the baseline and the 12-week follow-up question-
naire include:
The primary outcome:
[1] Hand pain: measured on a numeric rating scale
(NRS) of hand pain in the dominant hand during
the day when doing moderate hand activities. The
anchor points are no pain (0) to severe pain (10).
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Table 1 Content of the Baseline and 12-week follow-up questionnaires
Concept Measurement method Details 0-wks 12-wks
Demographic and Condition
Information
Date of birth ✓
Gender ✓
Time since RA or IA symptom onset ✓
Time since RA or IA diagnosis ✓
Employment status ✓
Marital status ✓
Living status (alone; or with family/
significant others)
✓
Medication regimen (i.e. what drugs
do they take for their arthritis);
✓
Whether received a steroid injection/
oral steroid in the last 6 weeks
✓
Hand dominance (i.e. whether they
consider this to be right, left or both).
✓
Primary outcome Hand Pain during activity 0-10 (0 = no pain/10 = severe pain) point numeric rating
scale of hand pain in the dominant hand during
the day [21]
✓ ✓
Secondary outcomes Hand Pain 0-10 (0 = no pain/10 = severe pain)
a) during a typical day during activities in the last week
in the non-dominant hand;
b) when resting- separately for the dominant and
non-dominant hands; and
c) at night –separately for the dominant and
non-dominant hands.
✓ ✓
Stiffness Measured separately for the dominant and
non-dominant hands:
a) Patient self-reported duration of early morning
stiffness affecting the hands (hours/min)
b) 0-10 point numeric rating scale of hand stiffness
(no (0) and severe (10) hand stiffness)
✓ ✓
Self-reported hand condition a five point rating scale of very severe/severe/
moderate/good/very good.
✓ ✓
Hand Function The Measure of Activity Performance
of the Hand (MAPHAND) [22, 23]
a self-reported measure of 18 items of performing
daily activities with the hands
✓ ✓
The Michigan Hand Outcomes
Questionnaire (MHQ) [24, 25]
assesses right and left hands separately: physical
status of the hand (movement, strength,
sensation: 5 items); daily activities performed with
the hands/arms (5 right and left; 7 bilateral); impact
of their condition on their normal activities (5 items);
pain frequency, severity and impact (5 items);
perceived appearance of their hands (4 items);
satisfaction with hand abilities (6 items)
✓ ✓
Disability The Health Assessment Questionnaire [26] 24 items of daily function ✓ ✓
Economic analysis EQ5D-3 L [27, 28] 5-items Scale (Mobility; Self-care; Usual activities;
Pain/Discomfort; Anxiety/Depression
✓ ✓
Your use of NHS and social services a) Any planned hospital overnight stays in the last
3 months
b) List of planned admissions
✓ ✓
Your use of hospital out-patient
appointments
a) Any planned hospital outpatient appointments
lasting 4 h or less in the last 3 months
b) If yes, department, speciality and number of
appointments
✓ ✓
Your use of day hospital appointments a) Any day or hospital outpatient lasting more than
4 h but not overnight during the last 3 months
b) If yes, department, speciality and number of
appointments
✓ ✓
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The pain NRS is a widely-used outcome measure in
RA clinical trials. During development and
psychometric testing of a patient-reported outcome
measure, it was identified that participants had a
strong preference for completing NRS over visual
analogue scales. This study also identified test-retest
reliability of pain (on movement and at rest) were
between rs = 0.70 to 0.72. The pain NRSs had
significant correlations (p < 0.001) with SF36v2
Bodily Pain scales (rs -0.69 to -0.77) [21] (Table 1).
And secondary outcomes including:
[2] Stiffness: measured through a) Patient self-reported
duration of early morning stiffness affecting the
hands (hours/minutes); b) 0-10 point numeric rating
scale of hand stiffness (with anchor points of no (0)
and severe (10) hand stiffness) - separately for the
dominant and non-dominant hands.
[3] Self-reported hand condition: a five-point rating scale
of very severe/severe/moderate/good/very good.
[4] Hand function: measured by the Measure of
Activity Performance in the Hand (Map-HAND),
which has been shown to be unidimensional and
Table 1 Content of the Baseline and 12-week follow-up questionnaires (Continued)
Your use of accident and emergency
services
a) Any A&E attendance in the last 3 months
b) If yes, the number of visits did not lead to
hospital admission
c) Were admitted into a hospital as an in-patient from
the A&E
d) If yes, department, reason for admission, where and
when admitted
✓ ✓
Your use of primary and community
based health services
a) Use of services such as GP, Practice nurse, Nurse,
Counsellor in the last 3 months
b) If yes, number of visits to each
✓ ✓
Your use of primary and community
based health services
a) Use of services such as, occupational therapy, Physio,
Care worker, Home help, Social worker, Other in the
last 3 months
b) If yes, number of visits to each
✓ ✓
Medication Current medication for RA/IA ✓
Any steroid injection/oral steroids
started in the last 12 weeks
Yes/No ✓
If yes, the date of the injection/started
taking oral steroids
DD/MM/YY ✓
Health Status Your own health state today Measured by a 0-100 vertical scale (0 = worst imaginable
state & 100 = best imaginable health state)
✓
Additional outcomes Any other upper limb occupational therapy or
physiotherapy treatment received in
the last 12 weeks
Type of treatment received ✓
Whether purchased or obtained from
elsewhere, any other “arthritis” gloves.
Yes/No ✓
If yes, what type these were ✓
How their hands are in comparison to
12 weeks ago, i.e. before receiving gloves
(much better/better/no change/worse/much worse) ✓
Concurrent use of any resting, wrist,
finger or thumb splints
✓
Adherence to glove wear During the day and at night for right/left hand gloves;
average time worn at night/during the day; average
number of days per week gloves have been worn
✓
Whether participants considered
gloves provided any benefit
Yes/No ✓
Whether they will continue to wear
the gloves provided
Yes/No ✓
If they considered the gloves of any
benefit, what were these
✓
Any problems encountered when
wearing gloves
Freetext ✓
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have good reliability and validity in a British RA
population [22, 23] and the Michigan Health
Questionnaire (MHQ), which assesses for the right
and left hands separately: physical status of the
hand (movement, strength sensation: 5 items); daily
activities performed with the hands/arms (5 right
and left; 7 bilateral); impact of their condition on
their normal activities (5 items); pain frequency,
severity and impact (5 items); perceived appearance
of their hands (4 items); satisfaction with hand
abilities (6 items) and also has good reliability and
validity [24, 25].
[5] Disability: the Health Assessment Questionnaire
(24 items of daily function) [26]
[6] Health-related quality of life (HRQoL) is measured
using the standardised five-item EuroQoL, 3-level
version (EQ-5D-3 L) [27, 28], which is recommended
by National Institute of Health and Clinical
Excellence (NICE) for economic evaluations in
clinical trials and has proven responsiveness, reliability,
and validity in trials of interventions for RA [29, 30].
The outcome measures within the baseline and 12-week
questionnaire are also listed in Table 1.
Patient interviews
At 14 weeks, participants (n = 10–15 from each group)
will be purposively selected to participate in a semi-
structured, face-to-face or telephone interview to investi-
gate their views on: benefits or negative effects of glove
wear (including when at work for those who are
employed); glove appearance, quality, comfort, ease of
applying; and willingness to buy gloves in future. Pur-
posive sampling will be based on: 1:3 male to female ra-
tio (as per the distribution of RA in population), and a
range of ages, baseline hand pain (mild/moderate/or se-
vere) and 12-week self-reported levels of adherence with
glove wear. The semi-structured interview schedule is
outlined in Table 2.
All interviews will be audio recorded, transcribed ver-
batim and thematically analysed by three researchers to
increase the validity of findings.
Fig. 1 A-GLOVES trial: flow of participants
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Sample size
This was calculated using data from the feasibility study.
Minimal clinically important differences for pain scales
in RA are estimated as 1.1 points on a 0–10 scale [31, 32].
The mean change in hand pain score during activity (mea-
sured four weeks post-intervention) was -1.03 (SD 2.22).
As the SD from the feasibility data might be an underesti-
mate, the 80% upper one-sided confidence limit of the
estimated SD, i.e. 2.48 was used. To identify a 1.1 point
difference, SD = 2.48, p = 0.05 and 80% power, 80 partici-
pants are required per group. Allowing for a 20% at-
trition (i.e. non-return of 12 week questionnaire and
a small number (up to 2%) not receiving a glove for
their dominant hand (because they only require a
glove for their non-dominant hand, and therefore not
providing primary outcome data), we intend to recruit
205 participants.
Recruitment
At each participating site a Principal Investigator (PI)
(senior occupational therapist/consultant rheumatologist)
will be identified, to be responsible for identification, re-
cruitment, consent and provision of baseline question-
naires, along with adherence to the study and treatment
protocols, following Good Clinical Practice Guidelines.
Members of the health care team and occupational
therapists at participating sites will identify adult pa-
tients with RA or IA and persistent hand pain during
the patients’ Rheumatology, occupational therapy or
hand therapy appointment. Either a research facilitator
or occupational therapist will then screen patients for
eligibility using the A-Gloves Trial Eligibility Screening
Form. (See Fig. 3 for recruitment procedure). All eligible
patients will be provided with a study explanation and
information pack. (See Additional file 1).
Enrolment Allocation
Post-Allocation
Close-out
Inter-
view
TIMEPOINT
-1 to 3 
weeks;
-21 to -1 
days
0w
Day 0
1-3w 
4-21 
days 
4-7w
28-49 
days
12w
84 days
16w
112 
days
ENROLMENT:
Eligibility screen X
A-Glove Trial Contact Details X
Informed consent X
Registration form X
Baseline assessment
given/mailed to patient X
Baseline assessment 
returned by patient X
Allocation X
INTERVENTIONS: (fitting 
and review appointments)
Intervention Glove X X
Placebo Glove X X
ASSESSMENTS:
Demographic data X
1: Hand pain during activity X X
2: Hand pain  rest/night;hand 
stiffness; hand function; 
disability; economic data
X X
Medication changes; other 
treatment; use  other gloves; 
perceived change hand 
status; adherence; perceived 
benefits and continuing use
X
OT Record Form Part 1 and 2 X X
Interview (selected 
participants)
X
Fig. 2 SPIRIT flowchart: schedule of enrolment, interventions and assessments
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If a site is encountering difficulty screening sufficient
numbers in clinics, then potential participants will be
identified from medical or occupational therapy records
by members of the health care team. The patient will
then be mailed a Study Information Pack by the research
facilitator or occupational therapist. (See Fig. 4 for
recruitment procedure).
At the screening stage, participants identified as having
had a steroid injection or started oral steroids in the last
six weeks, but who otherwise meet the inclusion criteria,
will not be consented but will be re-screened six weeks
after the date of steroid injection/starting oral steroids to
re-check trial eligibility. Steroids can reduce hand pain
and thus would be a confounding factor in evaluating
glove effectiveness. If at six weeks they are still eligible,
they will be re-approached for consent.
Participants may receive a steroid injection or start oral
steroids following consent. If this occurs between consent
and glove fitting, the occupational therapist will identify
this at the glove fitting appointment and defer glove fitting
for six weeks from the date of injection/steroid start. It is
not anticipated that this will be a common event. If the
participant starts steroids following glove provision and
their hands are still symptomatic, they will be advised to
continue glove wear as prescribed, as this is a pragmatic
trial. If the patient reports that their hands are no longer
causing them pain or discomfort they will be advised not
to wear the gloves. However, they will remain in the trial
and complete the 12-week questionnaire, as we will be
conducting an intention to treat analysis.
Following consent, by the research facilitator or occu-
pational therapist, participants will be provided with a
baseline (i.e. 0 weeks) questionnaire to complete and
return in a Freepost envelope to the trial manager. On
receipt of the completed questionnaire, the trial manager
will enter their details into a web-based MACRO
database (managed by Lancashire Clinical Trials Unit
[CTU]) and request that the unblinded CTU staff per-
form the assignment of the intervention.
Assignment of intervention
Allocation and sequence generation
Participants will be randomly assigned to either the inter-
vention or placebo glove group with a 1:1 allocation gen-
erated and delivered by ‘Sealed Envelope,’ an online,
central randomisation service (www.sealedenvelope.com).
The randomisation schedule will be stratified by whether
or not the participant has had a change in or received new
medication (specifically DMARDs or biologics) within the
last three months, using permuted blocks of random sizes.
Concealment mechanism
The block sizes or schedule will not be disclosed to the
trial manager, occupational therapists or research facili-
tators to ensure concealment. Randomisation will occur
only once the trial manager confirms a participant’s
eligibility, consent and that they have completed the
baseline questionnaire.
Implementation
Within three working days of notification by the trial
manager, unblinded CTU staff will perform the random-
isation and securely e-mail a referral for either interven-
tion or placebo gloves to the relevant site. Within three
weeks of referral, the occupational therapist will make
an appointment and provide the participant with the
appropriate gloves.
Blinding
Due to the nature of the intervention it will not be
possible for therapists to be blinded to group allocation.
As most sites will only have one Rheumatology occupa-
tional therapist, both intervention and placebo gloves
will commonly be provided by the same occupational
Table 2 A-GLOVES semi-structured qualitative interview schedule
A-GLOVES Trial: Qualitative Semi-structured Interview Schedule
Opening/Main Question
“Having worn the arthritis gloves for up to 12 weeks, could you tell me
about any negative or positive effects these have had on your hand
pain and hand problems?”
The following prompts may be used to expand on the answers given:
1 What effect did they have on your hand pain, hand stiffness and
ability to use your hands?
2 Were there any particular activities you found they helped with?
[For example: personal care; household activities; leisure/social
activities; driving; work].
3 Were there any particular activities you found they did not help
with? [For example: personal care; household activities; leisure/social
activities; driving; work].
4 How did you find wearing them?
5 How was it to put them on and off your hands?
6 Was there anything about the gloves or their effects which you
think helped/hindered your hand pain and hand problems?
7 If they were helpful: when did you find them helpful to wear: either
in the day or at night (or both)?
8 If they were not helpful: when did you find them unhelpful to wear:
either in the day or at night (or both)?
9 For those employed: Have you used them at work? If yes, were they
helpful? And in what ways? If not helpful, why was this?
10 Did you have any problems wearing the gloves?
11 What did you think of the gloves appearance?
12 What did you think of the quality of the gloves you were given?
13 How did you find cleaning them?
14 Would you consider buying them in the future?
15 Would you change anything about them to make it better for your
use? (e.g. colour, texture, amount of pressure applied, size, length)
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Fig. 3 Recruitment and consent flowchart: rheumatology clinic/occupational therapy
Fig. 4 Recruitment flowchart via medical/OT records/health care staff and study information pack mailed/provided to patient
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therapist. During the glove training and site monitoring
visits, the importance will be emphasised of not divul-
ging to the participant whether they are receiving an
intervention (arthritis glove) or a placebo glove.
Therapists will be asked not to use the term “compression”
glove (an alternative name for arthritis gloves in clinical
practice) in any participant interaction, as this may unblind
patients as to whether they are receiving an intervention or
placebo glove. Participants will be kept blinded to group
allocation by describing the study throughout as a
comparison of two types of arthritis glove and not
divulging the differences between these.
The trial manager will remain blinded to group alloca-
tion until the participant has completed and returned
their 12-week questionnaire and the data been verified
at the CTU. The trial manager will then be unblinded to
group allocation for some participants in order to
complete interviews with participants (n = 24–30).
Data co-ordination and data entry staff at the CTU,
responsible for baseline and 12 weeks questionnaires man-
agement, will be blinded to group allocation. However, data
entry for the Treatment Records (which identify the group
allocation) will be conducted separately by the CTU Trial
Management Team only, to avoid other CTU staff becom-
ing unblinded. Statisticians and the health economist will
be blinded to group allocation until analysis is complete.
Emergency unblinding
Not applicable as serious adverse events are not known
to occur in clinical practice.
Data collection methods
Outcomes will be collected via self-reported question-
naires at baseline (i.e. prior to randomisation) and
12 weeks later. Glove provision will usually occur within
three weeks of randomisation and referral to occupa-
tional therapy. Thus, at follow-up, most participants will
have worn gloves for about nine weeks. Feedback from
glove users indicates that they normally experience any
benefits within a short-time of commencing glove-wear.
The trial manager (baseline) and CTU (12 weeks) will
monitor return of all questionnaires and the quality of data.
 At 1 week after questionnaire provision/mailing, if
the questionnaire is not yet returned, the trial
manager [baseline questionnaire] or CTU [12-week
questionnaire] will telephone/text/e-mail
(as applicable) to remind the participant to
return their questionnaire.
 At 2 weeks after questionnaire provision/mailing, if
the questionnaire is not yet returned, the trial
manager [baseline questionnaire] or CTU [12-week
questionnaire] will mail a reminder letter and a
further copy of the relevant questionnaire
(with Freepost envelope).
 If the 12 week questionnaire is not returned by
week 16, the CTU will inform the trial manager
who will then telephone the participant to obtain a
minimal data set (i.e. at least dominant hand pain
during moderate activity and if gloves are being
worn (yes/no)). If possible, as much of the following
will also be collected: dominant hand pain at night;
hand stiffness; MAPHAND; hand condition severity
scale; how their hands are in comparison to
12 weeks ago, i.e. before receiving gloves (much
better/better/no change/worse/much worse). The
trial manager will complete the minimal dataset on a
12-week questionnaire (with participant’s PIN included),
identifying on the front page that it is a minimal dataset
completed by telephone. If the trial manager is unable
to obtain this data, this will be recorded in the Trial
Database and data entered as missing.
Data management
Data transfer from the University of Salford to CTU
The trial manager will ensure copies of all completed
baseline and completed/corrected 12-week question-
naires are provided, in a timely and secure manner (e.g.
copies of the questionnaires will be scanned and sent by
e-mail using encrypted PDF), to the CTU for data entry.
PDF scans of the questionnaires will be securely stored
in password protected restricted access folders on the
University of Central Lancashire network.
A written Data Management Plan (DMP), containing
more detail about the Data Management procedures is
available on request from the research team.
Baseline and 12 week questionnaires will be securely
stored at the CTU following CTU procedures. At the end
of the study, all electronic copies of participant question-
naires will be deleted and purged from the CTU network.
Any paper questionnaires and documents (originals or
copies) will be securely transferred to the University of
Salford. Interview recordings will be deleted following tran-
scription and analysis. Recordings and transcriptions will
be stored on a secure server at the University of Salford.
All data will be archived for three years in the Centre for
Health Sciences Research, University of Salford. Quantita-
tive data will become available to other researchers, on re-
quest, following completion and publication of the trial.
Statistical methods
Primary effectiveness analyses will follow a pre-specified
statistical analysis plan and will include the intention to
treat (ITT) population. The primary analysis will use
multiple linear regression to estimate the effect of group
allocation on hand pain during activity, controlling for
the stratification variable in the randomisation process
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(recent DMARD changes) and for the baseline value of
the hand pain score. Secondary analysis will repeat the
primary analysis method for all other outcomes, using
appropriate modelling approaches (i.e. multiple linear re-
gression, logistic regression or ordinal logistic regression,
controlling for the stratification variable and the baseline
value of the specific measure. Sensitivity analyses will
assess for any potential bias in the analysis of the pri-
mary outcome measure by excluding participants who
were not given gloves, were given the wrong gloves, or
who received steroids (oral or injection) between
randomisation and outcome measurement (per protocol
populations). Data will be analysed by person and using
dominant hand results, as reported by the participant.
No interim outcome analysis or sub group analysis will
be undertaken. We will not undertake any data imput-
ation for the primary analysis. We will undertake multiple
imputation of the primary outcome as a sensitivity ana-
lysis. Questionnaire responses on medication use, other
treatments, perceived benefit of gloves, continued glove
use, adherence and occupational therapist treatment
record data will be reported as numbers/proportions or
means/SD, with 95% confidence intervals. Analyses will be
undertaken in Stata version 14 or later [33].
Economic evaluation
The economic analysis will include costs to health and
social care service providers and health benefits to pa-
tients. The time horizon for the evaluation is 12 weeks
as per the scheduled trial follow-up. As such neither
costs nor outcomes will be discounted. The data will be
analysed on an intent-to-treat basis.
The measure of health benefit for the primary economic
analysis will be quality adjusted life years (QALYs). This
will be estimated from the EQ-5D-3 L and associated util-
ity tariffs. Secondary analysis will explore the cost-
effectiveness of arthritis gloves using the primary clinical
outcome measure, change in hand pain during moderate
activity between baseline and follow-up. The direct costs
of healthcare resources used during the trial will be esti-
mated by combining the level of use reported by partici-
pants with the unit cost specific to that resource. The unit
costs will be derived from published national average unit
cost data, the price year will be 2016. Total direct costs
will also include the cost of the gloves. Regression analysis
will be used to estimate the net total costs and economic
benefits of the arthritis gloves compared to the placebo
gloves, adjusting for baseline values and the stratification
variable (recent DMARD changes).
Cost-effectiveness will be measured as an incremental
cost-effectiveness ratio (ICER) for the arthritis gloves
versus the placebo gloves. As recommended by NICE
for health technology appraisals [34], cost-effectiveness
acceptability analysis will be conducted. Non-parametric
bootstrapping of the incremental costs and outcomes
(estimated from the regression analysis) will be used to
estimate the probability that arthritis gloves are cost-
effective compared to placebo gloves.
Data monitoring
The trial will not have a separate Data Monitoring
Committee (DMC), as the safety risks associated with this
study are very low. Consequently, there are no stopping
rules for safety. The project will be overseen by a Trial
Steering Committee (TSC), which will perform this
function.
Harms
There is minimal risk or discomfort associated with the
intervention (Isotoner) gloves. If a participant has
increased hand swelling due to an exacerbation of their
condition after glove provision, this can affect fit and
potentially cause tingling or numbness. The verbal and
written instructions provided during glove provision
emphasise that the participant should: regularly check
their hands; not wear the gloves continually; stop wear-
ing the gloves if they experience any discomfort or pain
or there is any redness or skin reaction; and contact the
occupational therapist if they experience any problems.
Glove use will be modified or discontinued by the
treating occupational therapist only if an adverse event
related to glove wear causes concern. This may occur at
the review appointment or if the participant contacts the
occupational therapist with concerns. Adverse events
caused by arthritis gloves have been identified in clinical
practice and therapists modify the wear regimen as
applicable. Adverse events and modifications include:
 Numbness; pins and needles; and/or fingertips
becoming discoloured (i.e. they go red, white or blue)
during glove wear. This may be due to gloves being
too tight. A larger glove may be fitted if this occurs.
 Allergic reaction or skin irritation can occasionally
occur. Gloves are either left off for a time and
re-tried or discontinued.
 Sleep disturbance at night. This can occur because
the gloves feel hot or itchy. Participants are
recommended to wear the gloves for part of the
night or leave them off when necessary.
It is unlikely any harm will arise from participants
wearing placebo gloves as most adverse events occur
due to pressure effects.
Any adverse event considered by the occupational ther-
apist to be resulting from glove wear, or any other minor
problems related to glove wear, will be recorded by the
occupational therapist on the A-Gloves Occupational
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Therapy Treatment Record Form at the review appoint-
ment and a copy returned to the CTU Data Manager.
Auditing
The trial manager will conduct at least one on-site mon-
itoring visit per year over the course of the study to all
clinical sites to educate, support and solve problems.
The trial manager will provide the research facilitator/
principal investigator with a site file checklist prior to
the visit and ask them to ensure the site file is up-to-
date. The trial manager will check the completed check-
list and site file at the visit. There will also be central
monitoring, by the CTU and trial manager, of quality of
source documentation, including consent form comple-
tion and adverse event reporting.
The Chief Investigator will permit study-related moni-
toring, audits and inspections by the Ethics Committee,
lead R&D department, the University and any NHS Trust
Research Governance Managers requiring this. The study
will be monitored in accordance with NHS and University
Research Governance procedures. The Chief Investigator
will ensure that any regulatory authority is given access to
all study related documents and study related facilities.
Principal investigators will be asked to audit their site files
at the beginning and end of the study using a checklist
provided by the University Research Centre and to allow
study related monitoring, audits and inspections as above.
Composition roles and responsibilities of: the co-ordinating
centres, TMG and TSC and data analysis team
Management of the trial is joint between the Centre for
Health Sciences Research, University of Salford (Hammond,
Prior) and Lancashire Clinical Trials Unit (Sutton). Prof
Hammond (Chief Investigator), Dr Prior (Trial Manager) at
the University of Salford, in conjunction with advice and
support from Dr Sutton (Lead, Lancashire CTU) and other
CTU staff, as appropriate, and Dr Cotterell (Statistician)
will be responsible for: (i) writing the study protocol and
any revisions, obtaining all study approvals and any
amendments, preparation of study documentation, study
planning, contributing to Trial Management Group and
Trial Steering Committee meetings, producing interim
and final reports to the funder and approving agencies
(ethics committees, Trust R&D departments) (ii) Serious
Adverse Event reporting (iii) Trial master file management
and ensuring sites have site files, and content is monitored
periodically (iv) Budget administration in conjunction with
Salford Royal NHSFT (Research & Development) and
University of Salford (Contracts Officer, Research and
Innovation) (v) Advice for Principal Investigators, Research
Facilitators and occupational therapists s (vi) Site initiation
visits with Research Facilitators/occupational therapists/
Principal Investigators (vii) Organising occupational ther-
apy training in glove provision and study procedures and
day-to-day management of the project. The Trial
Management Group (TMG) consists of AH (Chair) and
the protocol contributors (listed in author contributions),
and YP as the trial manager). The TMG will approve docu-
mentation, study protocol procedures, advise on ethics ap-
plication, monitor trial progress by reviewing the trial
progress reports, any problems arising, be advised of any
Serious Adverse Events, review findings and plan
dissemination. The TMG will meet at 6 monthly intervals
and receive reports of trial progress. Teleconferences and
ad-hoc meetings will be held during the study if issues arise
requiring discussion. The Trial Steering Committee (TSC)
consists of: Dr Peter Klimiuk, Consultant Rheumatologist,
Pennine Musculoskeletal Partnership Ltd, Oldham (Chair);
Cathy Ball, Research Clinical Specialist Hand Therapist,
Kennedy Institute for Rheumatology, Oxford; Dr Michael
Callaghan, Research Fellow, University of Manchester and
Clinical Specialist Physiotherapist, Manchester Royal
Infirmary; Mike Bradburn, Senior Medical Statistician,
Sheffield Clinical Trials Unit, SCHARR, University of
Sheffield. The TSC will meet three times and also act as the
Data Monitoring Committee (DMC) and provide trial over-
sight and data monitoring. The TSC will meet to approve
the protocol, advise on procedures and progress, data moni-
toring and review findings and monitor trial progress by
reviewing trial progress reports. The project does not have a
DMC, as the safety risks associated with this study are very
low. The TSC will have access to the unblinded data on
completion of the analysis. No interim analyses are planned.
Protocol amendments
Any subsequent modifications to the protocol which may
impact on the conduct of the study, potential benefit to the
patient or may affect patient safety (including changes of
study objectives, study design, patient population, sample
sizes, study procedures, or significant administrative aspects)
will require a formal amendment to the protocol. Such
amendment will be agreed by TMG and TSC members and
approved by the approving NRES Ethics Committee prior to
implementation and notified to the participating Trust R&D
departments in accordance with local regulations.
Administrative changes of the protocol are minor cor-
rections and/or clarifications that have no effect on the
way the study is to be conducted. These administrative
changes will be agreed upon by TMG members and doc-
umented in a Memorandum filed in the trial master file.
The approving NRES Ethics Committee may be notified
of administrative changes at the discretion of the TMG.
Protocols and documents will be version controlled.
Dissemination
Findings will be submitted to rheumatology and health
professional conferences and journals. A summary of
findings will be provided to relevant health professional
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and arthritis patient organizations, requesting these are
included in websites and newsletters. We will also pro-
duce guidelines, for both therapists and patients, on how
to correctly fit and wear arthritis gloves, based on the A-
GLOVES Trial Occupational Therapy Glove Provision
Manual [17] and disseminate these as above.
Discussion
This protocol describes a definitive, pragmatic, patient-
blinded, and multi-centre superiority randomised paral-
lel group trial, which aims to determine the effectiveness
and cost-effectiveness of the use of arthritis gloves for
people with RA or IA with persistent hand pain. The
results of this trial will inform the evidence base to
support the prescription of arthritis gloves for people
with RA or IA and hand pain. The results of this study
will be published as soon as they become available.
Additional file
Additional file 1: A-GLOVES: Testing Arthritis Gloves in Rheumatoid/
Inflammatory Arthritis. (DOC 446 kb)
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